ClinicalTrials.Veeva

Menu

Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination

U

University of Giessen

Status

Completed

Conditions

Covid19
Vaccination Reaction

Study type

Observational

Funder types

Other

Identifiers

NCT05043168
2021-100682-BO-ff

Details and patient eligibility

About

The study aims to summarize kidney histopathological findings in patients with coronavirus disease 2019 (COVID-19) and post-severe acute respiratory syndrome-coronavirus-type 2 (SARS-CoV-2) vaccination.

Full description

The SARS-CoV-2 pandemic has had substantial global morbidity and mortality. While COVID-19 is most commonly characterized as a respiratory illness, extrapulmonary manifestations are a prominent part its clinical spectrum. Kidney disease is a common finding in COVID-19, and has also been rarely described after SARS-CoV-2 vaccination. The main objective of this study is to summarize kidney histopathological findings in patients with COVID-19 and post-SARS-COV-2 vaccination, in whom native kidney biopsy was performed and samples were obtained by the Nephropathology Section, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Enrollment

42 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • being diagnosed with COVID-19 when kidney biopsy was performed
  • history of recent homologous or heterogenous vaccine regimen comprising either vector-based vaccines or messenger ribonucleic acid-based vaccines

Exclusion criteria

  • Patient refuses participation

Trial design

42 participants in 2 patient groups

Patients with COVID-19
Description:
Polymerase Chain Reaction-positive SARS-CoV-2 infection
Patients post-SARS-CoV-2 vaccination
Description:
Onset of kidney disease potentially relatable to SARS-CoV-2 vaccination based on clinical grounds

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems